Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Sassolas

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Melanoma Research|April 2, 2004
Cutaneous malignant melanoma and neurofibromatosis type 1Bernard Guillot, Sophie Dalac, Michele Delaunay, et al.
Clinical Laboratory|March 19, 2021
IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal Immunoglobulins in ScleromyxedemaTania Petersen, Thibault Mahévas, Pauline Cannet, et al.
Human Pathology|August 23, 2015
Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practiceArnaud Uguen, Paul Guéguen, Delphine Legoupil, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) studyJean Jacques Grob, Thomas Jouary, Brigitte Dréno, et al.
The British Journal of Dermatology|December 18, 2021
A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic featuresAlexis Barranca, Sébastien Debarbieux, Emmanuelle Tancrède-Bohin, et al.
Archives of Dermatology|May 20, 2009
Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort studyPhilippe Bernard, Ziad Reguiai, Emmanuelle Tancrède-Bohin, et al.
Chest|June 20, 2014
A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosisCatherine Droitcourt, Michel Rybojad, Raphaël Porcher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 6, 2022
Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyPatricia Senet, Hervé Maillard, Elisabeth Diot, et al.
Paediatric Drugs|June 4, 2019
Evaluation of Children with Psoriasis from the BiPe Cohort: Are Patients Using Biotherapies in Real Life Eligible for Phase III Clinical Studies?Céline Phan, Alain Beauchet, Anne-Claire Burztejn, et al.
Archives of Dermatology|June 22, 2005
Prediction of survival for patients with bullous pemphigoid: a prospective studyPascal Joly, Jacques Benichou, Catherine Lok, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Melanoma Research|April 2, 2004
Cutaneous malignant melanoma and neurofibromatosis type 1Bernard Guillot, Sophie Dalac, Michele Delaunay, et al.
Clinical Laboratory|March 19, 2021
IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal Immunoglobulins in ScleromyxedemaTania Petersen, Thibault Mahévas, Pauline Cannet, et al.
Human Pathology|August 23, 2015
Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practiceArnaud Uguen, Paul Guéguen, Delphine Legoupil, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) studyJean Jacques Grob, Thomas Jouary, Brigitte Dréno, et al.
The British Journal of Dermatology|December 18, 2021
A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic featuresAlexis Barranca, Sébastien Debarbieux, Emmanuelle Tancrède-Bohin, et al.
Archives of Dermatology|May 20, 2009
Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort studyPhilippe Bernard, Ziad Reguiai, Emmanuelle Tancrède-Bohin, et al.
Chest|June 20, 2014
A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosisCatherine Droitcourt, Michel Rybojad, Raphaël Porcher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 6, 2022
Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyPatricia Senet, Hervé Maillard, Elisabeth Diot, et al.
Paediatric Drugs|June 4, 2019
Evaluation of Children with Psoriasis from the BiPe Cohort: Are Patients Using Biotherapies in Real Life Eligible for Phase III Clinical Studies?Céline Phan, Alain Beauchet, Anne-Claire Burztejn, et al.
Archives of Dermatology|June 22, 2005
Prediction of survival for patients with bullous pemphigoid: a prospective studyPascal Joly, Jacques Benichou, Catherine Lok, et al.
Pageof 5